View, browse and sort the list of CPhI North America Conference sessions and show floor programming by pass type, track, and format. Seating is first come, first serve, so please arrive early to sessions that you would like to attend. Sessions are subject to change.
Dr. Azam was appointed President CEO of Tmunity Therapeutics in Dec 2016. Most recently Dr Azam was the Head of the Cell & Gene Therapies Unit at Novartis Pharmaceuticals and was a member of the Pharmaceutical Executive Committee. He has an extensive U.S., Global and International pharmaceutical industry background, with strong experiences in science, clinical development, regulatory and commercial activities. While at Novartis, he lived and worked in the USA and Switzerland. Previous roles at Novartis included Head of Global Medical Affairs & HEOR General Medicines, Chief Scientific Officer and Head of US Clinical Development & Medical Affairs and Global Head Regulatory Affairs for the Neurosciences & Ophthalmic Franchise.
Prior to Novartis he was the Chief Executive Officer of Novaccel Therapeutics LLC, a company he founded focusing on accelerating assets in the translational medicine setting. Prior to this he served as Chief Medical Officer at Aspreva Pharmaceutics Inc, a company that focused on orphan and rare autoimmune disease states. Aspreva was acquired by Galenica SA in 2008.Prior to this he worked at Johnson & Johnson in Pharmaceutical Research & Development and in Medical Devices at Johnson & Johnson Ethicon. He started his life-sciences career with Warner Lambert-Parke Davis in 1998.
Dr Azam is a graduate of the University of Liverpool, United Kingdom, where he completed undergraduate studies in Human Biology & Anatomy. He graduated from the University of Liverpool School of Medicine & attained board certification as an Obstetrician & Gynecologist in the U.K